Jeffreys, Laura N, Ardrey, Alison, Hafiz, Taghreed A, Dyer, Lauri-Anne, Warman, Ashley J, Mosallam, Nada, Nixon, Gemma L, Fisher, Nicholas E, Hong, W David, Leung, Suet C et al (show 11 more authors)
(2023)
Identification of 2-Aryl-Quinolone Inhibitors of Cytochrome bd and Chemical Validation of Combination Strategies for Respiratory Inhibitors against Mycobacterium tuberculosis.
ACS INFECTIOUS DISEASES, 9 (2).
pp. 221-238.
Abstract
<i>Mycobacterium tuberculosis</i> cytochrome <i>bd</i> quinol oxidase (cyt <i>bd</i>), the alternative terminal oxidase of the respiratory chain, has been identified as playing a key role during chronic infection and presents a putative target for the development of novel antitubercular agents. Here, we report confirmation of successful heterologous expression of <i>M. tuberculosis</i> cytochrome <i>bd</i>. The heterologous <i>M. tuberculosis</i> cytochrome <i>bd</i> expression system was used to identify a chemical series of inhibitors based on the 2-aryl-quinolone pharmacophore. Cytochrome <i>bd</i> inhibitors displayed modest efficacy in <i>M. tuberculosis</i> growth suppression assays together with a bacteriostatic phenotype in time-kill curve assays. Significantly, however, inhibitor combinations containing our front-runner cyt <i>bd</i> inhibitor CK-2-63 with either cyt <i>bcc</i>-<i>aa</i><sub>3</sub> inhibitors (e.g., Q203) and/or adenosine triphosphate (ATP) synthase inhibitors (e.g., bedaquiline) displayed enhanced efficacy with respect to the reduction of mycobacterium oxygen consumption, growth suppression, and <i>in vitro</i> sterilization kinetics. <i>In vivo</i> combinations of Q203 and CK-2-63 resulted in a modest lowering of lung burden compared to treatment with Q203 alone. The reduced efficacy in the <i>in vivo</i> experiments compared to <i>in vitro</i> experiments was shown to be a result of high plasma protein binding and a low unbound drug exposure at the target site. While further development is required to improve the tractability of cyt <i>bd</i> inhibitors for clinical evaluation, these data support the approach of using small-molecule inhibitors to target multiple components of the branched respiratory chain of <i>M. tuberculosis</i> as a combination strategy to improve therapeutic and pharmacokinetic/pharmacodynamic (PK/PD) indices related to efficacy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | bedaquiline, cytochrome bd oxidase, Q203, tuberculosis |
| Divisions: | Faculty of Science and Engineering > School of Physical Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 17 Feb 2023 11:31 |
| Last Modified: | 17 Feb 2023 11:32 |
| DOI: | 10.1021/acsinfecdis.2c00283 |
| Open Access URL: | https://pubs.acs.org/doi/full/10.1021/acsinfecdis.... |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3168453 |
Dimensions
Dimensions
